About 184,525 results

Agenus Withdraws BLA for Balstilimab in Metastatic Cervical Cancer

Oct 22nd, 2021 - The immuno-oncology company Agenus has made the decision to withdraw its biologic license application (BLA) for the use of the PD-1 inhibitor balstilimab in patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.1 The decision follows the full approval of pembrolizumab (Keytruda) on October 13, 2021, for use as a single agent in pat...

Children With Cancer At Higher Risk for Severe Illness from COVID-19

Oct 22nd, 2021 - Approximately 20% of pediatric patients with cancer infected with COVID-19 experienced severe illness, according to data published in The Lancet Oncology. Furthermore, deaths due to the infection were proportionally higher in this patient population compared with the general pediatric population, providing evidence that children with cancer are at higher risk of developing severe illness from C...

Dr. Yarchoan on Unique Characteristics of Fibrolamellar Carcinoma

Oct 22nd, 2021 - Mark Yarchoan, MD, assistant professor of oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses unique characteristics of fibrolamellar carcinoma (FC). FC is a distinct type of liver cancer, Yarchoan says. Unlike hepatocellular carcinoma (HCC), which typically occurs in older patients who have underlying liver disease like cirrhosis, FC tends to occur in youn...

Low androgen in kidney recipients tied to diabetes
Miriam E. Tucker

Oct 22nd, 2021 - Low androgen levels appear to be linked to the development of posttransplantation diabetes mellitus (PTDM) in male kidney transplant recipients, new research suggests. London_England/Thinkstock Among 243 men who did not have diabetes prior to undergoing kidney transplantation, levels of both dihydrotestosterone (DHT) and testosterone were inversely related to the risk for developing diabetes th.

COVID Vaccine Recipients Also Less Likely to Die of Other Causes

Oct 22nd, 2021 - People who were vaccinated against COVID-19 were also less likely to die from non-COVID-19-related causes compared with unvaccinated people, researchers found. The adjusted relative risk of non-COVID-19 mortality ranged from 0.31 (95% CI 0.30-0.33) for those who received two doses of Moderna to 0.54 (95% CI 0.49-0.59) for Johnson & Johnson recipients, reported Stanley Xu, PhD, of Kaiser Permane...

Myeloma Drug Pulled From Market Just Months After Approval

Oct 22nd, 2021 - Just months after FDA granted accelerated approval of its myeloma drug, Oncopeptides has pulled melphalan flufenamide (melflufen, Pepaxto) from the market. The decision followed an FDA hold on clinical trials of the drug after data from a confirmatory trial showed an increased mortality risk in patients treated with melflufen. The phase III OCEAN study compared melflufen plus dexamethasone and ...

NSCLC Incidence Declining, Except in Stage I Disease

Oct 22nd, 2021 - The overall incidence of non-small cell lung cancer (NSCLC) decreased from 2010 to 2017, with the incidence of stage IV disease falling, and stage I disease rising, researchers determined. A cross-sectional epidemiological analysis showed that NSCLC incidence per 100,000 population declined from 46.4 to 40.9 during the study period. While the incidence of stage II, IIIA, and IIIB disease was st...

A Wealth of Therapeutic Advances in Lung Cancer Stress a Need for Early NGS Testing

Oct 22nd, 2021 - The overwhelming number of options for the treatment of patients with lung cancer underscores the importance of broad molecular testing up front to ensure patients receive optimal care, said Stephen V. Liu, MD. Our strategies [for managing lung cancer] are becoming more sophisticated and precise, but the first step of broad next-generation sequencing [NGS] is really the key. NGS is essential t...

FDA Approves Companion Diagnostic for Adjuvant Atezolizumab in Stage II to IIIA NSCLC

Oct 22nd, 2021 - The FDA has approved the VENTANA PD-L1 (SP263) assay to assist in identifying which adult patients with stage II to IIIA non–small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on 1% or more of tumor cells are eligible to receive adjuvant atezolizumab (Tecentriq) following surgery and platinum-based chemotherapy.1 Adjuvant atezolizumab was approved for use in this indication on O...

Arterial Chemo Tops Chemoembolization for Large Liver Tumors

Oct 22nd, 2021 - Patients with unresectable large-volume liver cancer lived significantly longer when treated with hepatic-artery infusion chemotherapy (HAIC) than with transarterial chemoembolization (TACE), a randomized trial from China showed. Median overall survival (OS) increased from 16.1 months with TACE to 23.1 months with FOLFOX (leucovorin, fluorouracil, and oxaliplatin)-HAIC. Progression-free surviva...

Many States Frown Upon Medicaid Coverage of Penile Implants for ED

Oct 22nd, 2021 - SCOTTSDALE, Ariz. -- At least 21 states still don't provide Medicaid coverage for penile implants in patients with erectile dysfunction (ED), a new study found. In contrast, 49 states cover male urethral slings, and 48 states cover insertion of artificial urinary sphincters for male incontinence, reported John Barnard, MD, of West Virginia University in Morgantown, who presented the findings at...

Cabozantinib Shows Activity Against RCC Brain Metastases

Oct 22nd, 2021 - The tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx) showed promising activity against brain metastases from renal cell carcinoma (RCC), researchers reported. In a retrospective cohort study of 88 patients with RCC brain metastases, the intracranial response rate with cabozantinib was 55% (95% CI 36-73%) in those with progressing brain metastases without concomitant brain-directed local...

Dr. Hansen on the Utilization of BCMA-Directed Therapy in Multiple Myeloma

Oct 21st, 2021 - Doris Hansen, MD, assistant member, Moffitt Cancer Center department of blood and marrow transplant and cellular immunotherapy, discusses the utilization of BCMA-directed therapy in multiple myeloma. his is an exciting time for the treatment of patients with multiple myeloma, as several agents have been approved in the past few years, Hansen says. However, patients have passive responses with ...

Dr. Zhen on the Need for Novel Therapies in Poorly Differentiated Small-Cell-Type NETs

Oct 21st, 2021 - David Zhen, MD, assistant professor, University of Washington School of Medicine, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, physician, Seattle Cancer Care Alliance, discusses the need for novel therapies in poorly differentiated small-cell-type neuroendocrine tumors (NETs). Limited therapeutic progress has been made in poorly differentiated smal...

Guidelines for dementia and age-related cognitive changes
MDedge Family Medicine; Linda Girgis, MD

Oct 21st, 2021 - Dementia remains a major cause of disability in older adults. In addition, it places a strain on family members and other caregivers taking care of these patients.

No Benefit to Intensifying Diabetes Meds at Hospital Discharge

Oct 21st, 2021 - Some older folks discharged from the hospital left with a more intense -- and possibly unnecessary -- treatment regimen for their diabetes, according to findings from the VA health system. In a retrospective study of over 28,000 patients ages 65 and older with type 2 diabetes, about 11% were discharged with an intensified regimen, which seemed to yield a mixed bag of outcomes, as these patients...

A Silver Lining in Cancer; Dedicated Care for DCIS; New Vaccination Initiative

Oct 21st, 2021 - A patient with breast cancer discovers the silver lining in her diagnosis and treatment. (ASCO Connection) Innovent Biologics announced that the PD-1 inhibitor sintilimab plus bevacizumab biosimilar (Byvasda) significantly improved progression-free survival in advanced EGFR-positive non-small cell lung cancer that progressed on prior EGFR-inhibitor therapy. By means of a complete response lette...

Estimating insulin resistance may help predict stroke, death in T2D
Sara Freeman

Oct 21st, 2021 - Calculating the estimated glucose disposal rate (eGDR) as a proxy for the level of insulin resistance may be useful way to determine if someone with type 2 diabetes (T2D) is at risk for having a first stroke, Swedish researchers have found. purestock/Thinkstock In a large population-based study, the lower the eGDR score went, the higher the risk for having a first stroke became.

A 70-year-old man presents with firm papules on his hand and fingers
Donna Bilu Martin, MD, Susannah Berke, MD

Oct 21st, 2021 - Granuloma annulare (GA) is a benign cutaneous disorder with an unknown cause. All races and ages may be affected, although women are more often affected than men.

Lessons Learned May Hold the Key for Improving Outcomes in Fibrolamellar Carcinoma

Oct 21st, 2021 - Fibrolamellar carcinoma is an extremely rare form of liver cancer that affects approximately 1 in 5 million Americans.1 However, because the disease appears so infrequently, it may be underdiagnosed, said Mark Yarchoan, MD. He added that, with an annual age-adjusted incidence rate of just 0.02 per 100,000 in the United States, fibrolamellar carcinoma is so uncommon that investigators have yet t...